Bionomics Ltd ADR
Yahoo Finance • 11 months ago
10 Best Australian Stocks To Buy
In this piece, we will take a look at the ten best Australian stocks to buy. If you want to skip our coverage of some of the biggest stocks in Australia and how you might trade them, then you can skip ahead to 5 Best Australian Stocks To B... Full story
Yahoo Finance • last year
Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA and Solidifies Plans to Initiate the Registrational Program for BNC210 in Social Anxiety Disorder
Positive outcome of End-of-Phase 2 meeting with U.S. Food and Drug Administration (FDA) in September 2023 enables advancement of BNC210 into Phase 3 studies in Social Anxiety Disorder Company confirms agreement with the FDA on Phase 3 clin... Full story
Yahoo Finance • last year
Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)
ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant reduction in total PTSD symptom severity at 12 weeks. Statistically significant secondary endpoints showed improvements in depressive sympto... Full story
Yahoo Finance • last year
Bionomics Announces Update on the α7 Nicotinic Acetylcholine Receptor (nAChR) Positive Allosteric Modulator (PAM) Collaboration with MSD
Bionomics has collaborated with MSD to identify novel α7 nAChR PAMs suitable for the treatment of cognitive disorders like Alzheimer’s DiseaseBased on the learnings from Bionomics’ candidate BNC375, additional candidates have been develope... Full story
Yahoo Finance • 2 years ago
Bionomics to Present at Upcoming June Investor Conferences
ADELAIDE, Australia and CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion chann... Full story
Yahoo Finance • 2 years ago
Bionomics Reports Promising Full Results Analysis from PREVAIL Phase 2 Study of BNC210 Social Anxiety Disorder (SAD)
Both doses of BNC210 as an acute treatment resulted in reductions in anxiety across multiple phases of the public speaking challenge Results achieved statistical significance in post-hoc analysis of the full data set and in relevant subpop... Full story
Yahoo Finance • 2 years ago
Bionomics First Half 2023 Earnings: AU$0.012 loss per share (vs AU$0.013 loss in 1H 2022)
Bionomics (ASX:BNO) First Half 2023 Results Key Financial Results Net loss: AU$16.2m (loss widened by 24% from 1H 2022). AU$0.012 loss per share. earnings-and-revenue-history All figures shown in the chart above are for the trailing 12... Full story
Yahoo Finance • 2 years ago
Bionomics Limited Announces Pricing of Underwritten Offering of American Depositary Shares in the United States
ADELAIDE, Australia, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO, Nasdaq: BNOX), (“Bionomics” or the “Company”), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to... Full story
Yahoo Finance • 2 years ago
Bionomics reports Full Year Financial Results
Bionomics Ltd ADELAIDE, Australia, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX:BNO, Nasdaq:BNOX), today announced its financial results for the 12 months ended 30 June 2022. Bionomics is a clinical stage biopharmaceutical co... Full story
Yahoo Finance • 3 years ago
Novamind to Host Bionomics’ PREVAIL Trial for Acute Treatment of Social Anxiety Disorder
TORONTO, ON / ACCESSWIRE / May 10, 2022 / Novamind Inc.(CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, today announced it has been selected to host a clinic... Full story
